1. Scrip
  2. >>Therapy Areas
  3. >>Anticancer

Roche Withdraws Tecentriq’s Frontline Bladder Cancer Indication, Ceding Market To Keytruda

 
• By Alaric DeArment

The move marks the second time since last year that Roche has withdrawn a urothelial carcinoma indication after its confirmatory trial failed to show an overall survival benefit.

Roche withdrew the first-line metastatic urothelial carcinoma indication for Tecentriq • Source: Shutterstock

Roche Holding AG’s PD-L1 inhibitor Tecentriq (atezolizumab) is losing one of its US Food and Drug Administration approvals as the Swiss drug maker is withdrawing its indication for first-line metastatic urothelial carcinoma. The move is one of multiple setbacks that PD-1 and PD-L1 checkpoint inhibitors have experienced in that setting and leaves Merck & Co., Inc.’s Keytruda (pembrolizumab) as the major player.

Roche’s Genentech division said 28 November that it would voluntarily withdraw the indication for Tecentriq in adults with locally advanced...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

ASCO: Kite’s Glioblastoma CAR-T Highlights Solid Tumor Progress

 
• By Alaric DeArment

The company presented Phase I data for CART-EGFR-IL13Rα2, showing patient responses in the notoriously hard-to-treat and deadly brain cancer.

Will Pfizer Walk Away From Arvinas After PROTAC Disappointment?

 
• By Andrew McConaghie

Arvinas and Pfizer have just filed the potential first-in-class protein degrader vepdegestrant, but its diminished commercial prospects after mixed Phase III data mean Pfizer could exit.

ASCO: Carvykti Data Raise Possibility Of Myeloma Cure

 
• By Alaric DeArment

J&J presented data at the American Society of Clinical Oncology meeting showing more than five-year disease- and therapy-free survival, but a myeloma working group will need to define what makes a cure.

Merus Raises $300m After ASCO Success

 
• By Andrew McConaghie

The company is raising the money to fuel development of its head and neck cancer candidate, petosemtamab, on the back of promising early data. Some analysts are stopping short of declaring it the winner against a rival product from Bicara, however.

More from Therapy Areas

Lyra Eyes US Filing For LYR-210 After Surprise ENLIGHTEN 2 Win

 
• By Sushmita Panda

In a turn of fortunes, Lyra Therapeutics has reported positive Phase III results for LYR-210 in chronic rhinosinusitis, boosting hopes for US approval. The company plans to submit an NDA and pursue further trials, but its cash position is precarious.

Ascletis Plans China Submission After Positive Denifanstat Phase III Acne Results

 
• By Sushmita Panda

Once-daily oral FASN inhibitor denifanstat meets all endpoints in a Chinese Phase III trial for moderate-to-severe acne, paving the way for a regulatory submission in China.

New Regenxbio DMD Data Support Gene Therapy Accelerated Approval

 
• By Joseph Haas

Regenxbio reported functional and biomarker data from an ongoing study of RGX-202, which it hopes to file for approval in Duchenne muscular dystrophy in 2026.